Navigation Links
Final Data From the Bioheart Seismic Trial Suggest Safety, Efficacy of Autologous Stem-Cell Therapy for Treating Congestive Heart Failure
Date:4/1/2008

Leading Expert Discusses Study During Late-Breaking Presentations at ACC

CHICAGO, April 1, 2008 /PRNewswire-FirstCall/ -- Bioheart, Inc. (Nasdaq: BHRT) announced today that final six-month, follow-up patient data was presented today during the late-breaking clinical trial sessions at the American College of Cardiology, suggesting that MyoCell(R) myoblast clinical cell therapy is a safe and potentially effective alternative treatment to standard medical therapy alone for improving heart function among patients with previously implanted cardiac devices who are experiencing congestive heart failure.

The findings from the SEISMIC(1) Trial, a 40-patient, randomized, multicenter, controlled, Phase II-a study conducted in Europe, evaluated MyoCell myoblast clinical cell therapy delivered via the MyoCath(R), endoventricular needle-injection catheter in patients previously fitted with implanted cardiac defibrillators(ICDs), receiving standard medical therapy and who are experiencing congestive heart failure. On admission to the trial, patients were randomized on a two-to-one ratio into the treatment versus control groups with 26 patients receiving MyoCell therapy and 14 patients in the control group. All patients were experiencing congestive heart failure and were previously fitted with ICDs and receiving standard medical therapy. Both the MyoCell biologic therapy and the MyoCath needle-injection catheter, developed by Bioheart, Inc., are currently being studied as investigational products.

"The results from the SEISMIC Trial are encouraging," said Prof. Patrick W. Serruys, MD, PhD, Principal Investigator and Chief, Department of Interventional Cardiology, Thoraxcenter, Erasmus Medical Center - Rotterdam, the Netherlands. "While
'/>"/>

SOURCE Bioheart, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Final Data From the SEISMIC Trial Suggest Safety, Efficacy of Autologous Stem- Cell Therapy for Treating Congestive Heart Failure
2. Nventa Enrolls and Initiates Dosing of Final Cohort in HspE7 Phase 1 Cervical Dysplasia Trial
3. Oral Talactoferrin Alfa Improves Overall Survival in Patients With Refractory Non-Small Cell Lung Cancer: Final Phase 2 Study Results Presented at the 8th Annual Targeted Therapies for the Treatment Of Lung Cancer Meeting
4. Daiichi Sankyo and Forest Laboratories Finalize Contract for Co-Promotion of AZOR(TM)
5. Aegerion Pharmaceuticals, Inc. Presents Final Results of Phase II Clinical Trials for AEGR-733 at Drugs Affecting Lipid Metabolism (DALM) 2007 Conference
6. Hope for Emphysema Sufferers: Clinical Trial That May Help Patients Breathe Easier Begins at Central DuPage Hospital
7. TAXUS(R) Stent Demonstrates Similar Outcomes in Diabetic Patients Compared to Non-diabetics in Pooled Analysis of TAXUS IV and V Trials
8. Major Deficiencies in Design; Funding of Clinical Trials Affects Future of Scientific Innovation
9. InterMune Announces Top-Line Results of Phase 1b Trial of ITMN-191 (R7227) and Provides Program Update
10. CVBT Appoints Dr. Nabil Dib as Principal Investigator for Phase II Heart Trial
11. ThromboGenics Completes Patient Enrolment in the Phase IIb Trial of Microplasmin in Vitrectomy (MIVI III)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... , Aug. 21, 2014   Memorial Hermann Health ... Cancer Center today announced a new partnership to provide ... of community breast care centers in the greater ... MD Anderson will become the exclusive provider of professional breast ... centers, located in Memorial City, The Woodlands ...
(Date:8/21/2014)... , Aug. 21, 2014  Publicis Groupe customer ... , Managing Partner and Healthcare Industry Group Leader, has ... which recognizes the most inspiring people in the life-sciences ... in research and development, marketing, technology, creativity, strategy and ... 2006 as a partner in its leading Rosetta Consulting ...
(Date:8/21/2014)... , N.Y. and HAMBURG, Germany , ... announced it is collaborating with Deutsches Elektronen-Synchrotron ( DESY ... Germany , to speed up management and storage ... Big Data and Analytics architecture based on IBM ... per second of data at peak performance and help ...
Breaking Medicine Technology:Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 2Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 4Shannon Hartley Shines in PharmaVOICE 100 2DESY and IBM Develop Big Data Architecture for Science 2DESY and IBM Develop Big Data Architecture for Science 3
... -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX ... outsourcing company with operations in China and the United ... for the second quarter of 2011 after the New ... (which will be Thursday morning, August 11, 2011 Shanghai ...
... For the fourth year, the Fondation,Médéric Alzheimer and ... psychosocial,interventions for people with dementia and their carers. The,purpose ... share best,practices. Applications can be submitted from today 19 ... . Psychosocial research involves or relates to ...
Cached Medicine Technology:WuXi PharmaTech Schedules Second-Quarter 2011 Earnings Release 24th Alzheimer's Awards Announced in Search of Global Solutions for Better Dementia Care 2
(Date:8/21/2014)... 2014 Top10BestSEOHosting.com has recently compared ... iPage ( http://www.top10bestseohosting.com/go/iPage/ ) is one of the ... , The manager of Top10BestSEOHosting.com states, “It is ... Actually, these companies have outperformed their competitors on ... People can get the best web hosting at ...
(Date:8/21/2014)... (PRWEB) August 21, 2014 An increasing ... a taxpayer that their federal tax payment is being ... appears to come from the IRS, “tax@irs.gov”, it’s actually ... provide personal and financial information. , While similar scams ... an uptick in phishing activity is occurring right now. ...
(Date:8/21/2014)... Patients with advanced laryngeal cancer appear to have ... than nonsurgical chemoradiation. , Author: Uchechukwu C. Megwalu, ... at Mount Sinai, New York, and colleagues. , ... cancer are diagnosed each year and squamous cell ... tumors. Prior to 1991, total surgical removal of ...
(Date:8/21/2014)... at a low or very low birth weight may ... diabetes. The findings, which appear in Diabetes Care ... type 2 diabetes in African American populations, which has ... from Boston University,s Slone Epidemiology Center followed more than ... over the course of 16 years, analyzing characteristics such ...
(Date:8/21/2014)... 21, 2014 (HealthDay News) -- Among seniors, dimming vision ... The study involved more than 2,500 people, aged 65 to ... and again two, six and eight years later. Vision ... person,s risk of death during the study period, the researchers ... researchers led by Sharon Christ of Purdue University in West ...
Breaking Medicine News(10 mins):Health News:iPage Reviews Unveiled Online At Top10BestSEOHosting.com 2Health News:Beware Of Phony “Tax Payment Rejected” IRS Emails 2Health News:Surgery associated with better survival for patients with advanced laryngeal cancer 2Health News:Low birth weight linked to higher incidence of type 2 diabetes in African American women 2Health News:Failing Vision Tied to Shorter Lifespans for Seniors 2
... Service Helps Providers Better Partner with Patients in ... Deepening its commitment to empowering patients and ... & Associates, LLC, a firm of strategic healthcare ... has established a new, first-of-its-kind service called Patient ...
... New Orleans, LA Xiaoming, Xu, PhD, Associate ... Health Sciences Center New Orleans School of Dentistry, ... of $1.77 million over four years by the ... fluoride-releasing, and bioactive dental materials including dental composites, ...
... Fla.--A new blood test used in combination with a ... of prostate cancer diagnosis, and could eliminate tens of ... according to a study led by researchers at Dana-Farber ... American Society of Clinical Oncology in Orlando, Fla., William ...
... Estimator(TM) Gives Patients Visibility into Treatment Costs before ... with the high number of uninsured and underinsured ... in consumer-driven health plans, such as Health Savings ... their own healthcare costs. As a result, hospitals ...
... Now, no matter when a patient with the ... a Spanish-speaking representative is available to help. Insulet Corporation ... insulin pump technology with its OmniPod System, has expanded ... a day, seven days a week."Managing diabetes is a ...
... NEW YORK, May 28 A new history of shock ... They Don,t Want You to Know About Shock Treatment" ( ... the Food and Drug Administration,s failure to investigate the devices ... is timely due to the FDA,s recent decision to call ...
Cached Medicine News:Health News:Gullapalli & Associates Launches First-of-Its-Kind Patient Centered CME(TM) (PCCME(TM)) Service, Names Dora Ochsenbein Manager of Educational Planning 2Health News:Gullapalli & Associates Launches First-of-Its-Kind Patient Centered CME(TM) (PCCME(TM)) Service, Names Dora Ochsenbein Manager of Educational Planning 3Health News:Gullapalli & Associates Launches First-of-Its-Kind Patient Centered CME(TM) (PCCME(TM)) Service, Names Dora Ochsenbein Manager of Educational Planning 4Health News:New blood test greatly reduces false-positives in prostate cancer screening 2Health News:Craneware Supports Hospitals' Compliance and Upfront Collections with Accurate Estimates 2Health News:Craneware Supports Hospitals' Compliance and Upfront Collections with Accurate Estimates 3Health News:Craneware Supports Hospitals' Compliance and Upfront Collections with Accurate Estimates 4Health News:Spanish-Speaking OmniPod Customer Support Now Available Around-the-Clock 2Health News:Spanish-Speaking OmniPod Customer Support Now Available Around-the-Clock 3Health News:New Book Highlights Human Cost of FDA's Failure to Investigate Medical Devices 2
Blunt tipped forceps with tungsten carbide treated jaws for enhanced gripping and removal of large sized foreign bodies....
Blunt tipped forceps with entire interior surface of tip serrated. For general purpose membrane grasping (coarse membranes)....
The Tano Asymmetrical Microforceps features an offset tip which allows optimal visualization along the entire tip length. Versatile tip design targets ILM, fine epiretinal membranes and diabetic or P...
Microforceps : Eckardt End & Side Gripping Forceps...
Medicine Products: